KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $227.7 million.

  • Biomarin Pharmaceutical's Short-term Investments fell 1069.23% to $227.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $227.7 million, marking a year-over-year decrease of 1069.23%. This contributed to the annual value of $194.9 million for FY2024, which is 3885.33% down from last year.
  • Biomarin Pharmaceutical's Short-term Investments amounted to $227.7 million in Q3 2025, which was down 1069.23% from $218.3 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year Short-term Investments high stood at $572.0 million for Q1 2023, and its period low was $194.9 million during Q4 2024.
  • For the 5-year period, Biomarin Pharmaceutical's Short-term Investments averaged around $378.4 million, with its median value being $420.2 million (2021).
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Short-term Investments surged by 3291.31% in 2022, and later tumbled by 4762.67% in 2024.
  • Over the past 5 years, Biomarin Pharmaceutical's Short-term Investments (Quarter) stood at $426.6 million in 2021, then skyrocketed by 32.91% to $567.0 million in 2022, then crashed by 43.8% to $318.7 million in 2023, then crashed by 38.85% to $194.9 million in 2024, then rose by 16.87% to $227.7 million in 2025.
  • Its Short-term Investments stands at $227.7 million for Q3 2025, versus $218.3 million for Q2 2025 and $223.5 million for Q1 2025.